Thrombotic Microangiopathy with Complement Factor H Gene Mutations Unassociated with Atypical Hemolytic Uremic Syndrome

Thrombotic Microangiopathy with Complement Factor H Gene Mutations Unassociated with Atypical Hemolytic Uremic Syndrome

Bibliographic Details
Main Authors:	Yesim Oymak, Tuba Hilkay Karapınar, Yılmaz Ay, Esin Özcan, Neryal Müminoğlu, Sultan Aydın Köker, Ersin Töret, Afig Berdeli, Erkin Serdaroğlu, Canan Vergin
Format:	Article
Language:	English
Published:	Galenos Publishing House 2015-07-01
Series:	Turkish Journal of Hematology
Subjects:	thrombotic microangiopathy eculizumab ahus cfh gene
Online Access:	https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-99705

Similar Items

Pregnancy-Associated Atypical Hemolytic Uremic Syndrome: A Case Report with <i>MCP</i> Gene Mutation and Successful Eculizumab Treatment
by: Alex Domínguez-Vargas, et al.
Published: (2024-01-01)

Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP
by: Kata Kelen, et al.
Published: (2023-09-01)

Eculizumab Treatment for Postpartum HELLP Syndrome and aHUS—Case Report
by: A. Inkeri Lokki, et al.
Published: (2020-04-01)

Treatment of Chemotherapy-Induced Thrombotic Microangiopathy with Eculizumab in a Patient with Metastatic Breast Cancer
by: Martin Hausberg, et al.
Published: (2019-01-01)

Eculizumab for bevacizumab induced thrombotic microangiopathy: A case report
by: Mihriban İnözü, et al.
Published: (2022-12-01)

Familial atypical hemolytic uremic syndrome with positive p.S1191L (c.3572C>T) mutation on the CFH gene: A single-center experience
by: Ersoy Dursun F, et al.
Published: (2021-07-01)

Transplant-associated Thrombotic Microangiopathy Treated with Eculizumab and Romiplostim
by: Muhammad Awidi, et al.
Published: (2021-02-01)

Atypical hemolytic uremic syndrome: Unique clinical presentation linked to rare CFHR5 mutation
by: Sofia Menotti, et al.
Published: (2021-11-01)

Compound Haplotype Variants in <i>CFH</i> and <i>CD46</i> Genes Determine Clinical Outcome of Atypical Hemolytic Uremic Syndrome (aHUS)—A Series of Cases from a Single Family
by: Agnieszka Furmańczyk-Zawiska, et al.
Published: (2021-04-01)

Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management
by: Mustafa N. Yenerel
Published: (2014-08-01)

Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option
by: Elena Román, et al.
Published: (2017-09-01)

Underlying Genetics of aHUS: Which Connection with Outcome and Treatment Discontinuation?
by: Andrea Spasiano, et al.
Published: (2023-09-01)

Pregnancy in Complement-Mediated Thrombotic Microangiopathy: Maternal and Neonatal OutcomesPlain Language Summary
by: Natalja Haninger-Vacariu, et al.
Published: (2023-07-01)

Clinical features of children with anti-CFH autoantibody-associated hemolytic uremic syndrome: a report of 8 cases
by: Qian Li, et al.
Published: (2022-12-01)

Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report
by: Ludovica Facchini, et al.
Published: (2017-07-01)

The conundrum of postpartum thrombotic Microangiopathy: case report and considerations for management
by: Katharina Artinger, et al.
Published: (2019-03-01)

Thrombotic microangiopathy in rheumatology: a link between thrombosis and autoimmunity
by: Evgeny L. Nasonov, et al.
Published: (2020-06-01)

Pediatric Atypical Hemolytic Uremic Syndrome Advances
by: Rupesh Raina, et al.
Published: (2021-12-01)

The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report
by: Magnus Holter Bjørkto, et al.
Published: (2021-02-01)

A rare sporadic case of C3 gene mutation in 5-month-old baby girl with atypical hemolytic uremic syndrome, with good prognosis
by: Abdullah A Baothman, et al.
Published: (2018-01-01)

A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy
by: Rachael D. Wright, et al.
Published: (2020-06-01)

Atypical Hemolytic Uremic Syndrome post Kidney Transplantation: Two Case Reports and Review of the Literature
by: Sami eAlasfar, et al.
Published: (2014-12-01)

Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre
by: Maximilien Grall, et al.
Published: (2021-07-01)

Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition
by: Lorenzo Catanese, et al.
Published: (2023-06-01)

Hemolytic-uremic syndrome: 24 years’ experience of a pediatric nephrology unit
by: Ana Sofia Vilardouro, et al.
Published: (2022-04-01)

Complement System as a New Target for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy
by: Gianluigi Ardissino, et al.
Published: (2022-07-01)

Eculizumab treatment in a patient with hematopoietic stem cell transplantation-associated thrombotic microangiopathy and steroid-refractory acute graft versus host disease
by: Cristina Fernández, et al.
Published: (2015-12-01)

Two cases of carfilzomib‐induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma
by: Michael Rassner, et al.
Published: (2021-01-01)

New in the differential diagnosis of different variants of thrombotic microangiopathies in obstetrics
by: T. V. Kirsanova, et al.
Published: (2021-04-01)

Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era
by: Sara Madureira Gomes, et al.
Published: (2021-04-01)

Thrombotic Microangiophatic in the ICU, postpartum hemolytic uremic syndrome: case report
by: Zulma Urbina, et al.
Published: (2016-07-01)

Thrombotic Microangiopathy as a Life-Threatening Complication of Long-Term Interferon Beta Therapy for Multiple Sclerosis: Clinical Phenotype and Response to Treatment—A Literature Review
by: Marco Allinovi, et al.
Published: (2024-03-01)

Complement Blockade Is a Promising Therapeutic Approach in a Subset of Critically Ill Adult Patients with Complement-Mediated Hemolytic Uremic Syndromes
by: Renaud Prével, et al.
Published: (2022-02-01)

Thrombotic Microangiopathy After Kidney Transplantation: An Underdiagnosed and Potentially Reversible Entity
by: Ana Ávila, et al.
Published: (2021-04-01)

A Multicenter Study Evaluating the Discontinuation of Eculizumab Therapy in Children with Atypical Hemolytic Uremic Syndrome
by: Saeed AlZabali, et al.
Published: (2022-11-01)

Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study
by: Jan Menne, et al.
Published: (2019-04-01)

Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy
by: Idris Boudhabhay, et al.
Published: (2021-06-01)

Purtscher-Like Retinopathy Associated with Atypical Hemolytic Uremic Syndrome
by: Melih Ustaoğlu, et al.
Published: (2017-12-01)

Case report: Novel FHR2 variants in atypical Hemolytic Uremic Syndrome: A case study of a translational medicine approach in renal transplantation
by: Emma Diletta Stea, et al.
Published: (2022-11-01)

Critical appraisal of eculizumab for atypical hemolytic uremic syndrome
by: Palma LMP, et al.
Published: (2016-04-01)